Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
about
Pharmacokinetics of Lidocaine Hydrochloride Administered with or without Adrenaline for the Paravertebral Brachial Plexus Block in DogsIn silico, experimental, mechanistic model for extended-release felodipine disposition exhibiting complex absorption and a highly variable food interactionIndividualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products.Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria.Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.Oral pharmacokinetics of the acidic drugs, diclofenac and sulfamonomethoxine in male Shiba goatsFlip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug developmentPopulation Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Development and validation of an UPLC-Q/TOF-MS assay for the quantitation of neopanaxadiol in beagle dog plasma: Application to a pharmacokinetic study.Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.A note on population analysis of dissolution-absorption models using the inverse Gaussian function.A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects.The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune diseasePros and cons of methods used for the prediction of oral drug absorption.Population Pharmacokinetic Model of Transdermal Nicotine Delivered from a Matrix-Type Patch.Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulationsA comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension.Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.Application of the convection-dispersion equation to modelling oral drug absorption.Absorption of rivastigmine from different regions of the gastrointestinal tract in humans.Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882.Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube.Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.Anemarrhena asphodeloides Non-Steroidal Saponin Components Alter the Pharmacokinetic Profile of Its Steroidal Saponins in Rat.HPLC-MS/MS method for the determination of four lignans from Phyllanthus urinaria L. in rat plasma and its application.A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets.Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.Study on the PK profiles of magnoflorine and its potential interaction in Cortex phellodendri decoction by LC-MS/MS.
P2860
Q28469477-5E279A6C-960E-496B-B623-FE0426B3AA19Q28543408-7A0D64CE-00D5-4A96-9A20-020200CC1080Q30534387-C256E022-D9E3-45F9-858B-F05C707585C0Q34215568-A37E9CC2-42DC-40FB-8C4F-35305B0139E8Q34922985-ECEEDEFE-0661-498D-BD83-6B491D713543Q34993096-48A1F4E1-3EFD-4742-A352-F39195903B80Q35105858-A028637D-7518-4AFA-ABAF-8FE94BB7F2EEQ35147092-F39EF73A-FF08-41C3-9230-1ACC4E81190AQ35153417-0EED6DB3-8732-4690-BE35-69C16B249AD5Q35967888-7ADA02A5-9100-428A-A8CF-C4E67F42456DQ36176846-08D26720-A3A8-4B29-A342-2D7667161DE1Q36595924-82222850-304D-4470-96D4-DAB8DD83078CQ36909306-43D7336E-7C65-4CC9-9A8F-9F5A7813712FQ37111029-011386E6-0DCD-4554-9FCB-1137AC4DF3D9Q37701151-1C466D1D-91FD-4E9F-BFA6-3EA3CDF71D4BQ37818144-9C57553C-2542-4808-BE03-4FCAB733A314Q38177366-35D03543-227C-4756-A714-F2E8243CD767Q38644169-FE3B774F-38BE-4C9D-AD6B-4A2DAC152D28Q38762087-1D64A7FD-3939-42AA-8751-8B9DBF5F159DQ38772200-64C0619F-C837-488A-AE5C-5B19EAD5928EQ38818562-2AA452E9-4CC0-49EB-A6C2-998149BA909BQ38896107-D9B6BBA8-15E5-457C-8E31-57A64C7FCDE9Q39289346-1D0F193D-9E39-4AEE-8299-DE312552928FQ39816357-5A540FCD-201B-439D-B321-EAD60E05193FQ40905288-BFDEB5F6-0267-4E42-8CF4-5F0FEAFBEE32Q42145370-4E583544-7A9C-4003-A69D-AC2226C66C0FQ44897896-9B147A14-B05D-42AC-A33E-1446ADFF8DB1Q45160680-FA26FE50-D045-46EF-83DE-094BDA98E2CEQ46100684-9B4D8681-F7CE-4AFD-9E56-6A3FEBD0A6FEQ47689257-710C55C8-EA99-4934-B055-156EFC83F13DQ47956948-5BA8C06F-3CC3-434C-A989-1C7409D65811Q48296458-E041AF34-2EA8-43BC-B2ED-D4BFA43DA1B4Q49011172-4BFA3631-6A62-40C7-B5D7-1240B867753FQ51371983-0EF8714D-9947-4FE9-8A25-332C8151E69BQ51985975-922166FC-F671-485F-8368-168086A66ED7Q53193563-D50A5313-D7AD-4CC1-8CE7-D7E4A009FC8EQ53543525-5060089B-F13D-4880-9483-D534C5BC2A5DQ53592528-AEC456C9-D254-4CA0-8157-98CC2EDEBC59Q53600844-24E30D99-688E-49F9-8E9C-BADA95B6CF0EQ54441884-7F0AA92A-BF19-4052-9F75-E18A261C5B07
P2860
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@ast
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@en
type
label
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@ast
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@en
prefLabel
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@ast
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@en
P2860
P356
P1476
Pharmacokinetic strategies in deciphering atypical drug absorption profiles.
@en
P2093
Honghui Zhou
P2860
P304
P356
10.1177/0091270002250613
P577
2003-03-01T00:00:00Z